Press and Media

Jan. 10, 2025

Introducing Neurogen Biomarking

Neurogen Biomarking is the first comprehensive platform designed to enable early detection and care for Mild Cognitive Impairment (MCI) and dementia associated with Alzheimer’s disease (AD). Neurogen Biomarking’s driving force is to solve the issue of delayed detection and ultimately diagnosis by empowering patients in a scientifically and clinically controlled ecosystem while also guiding them every step of the way in their brain health journey.

Jan. 14, 2025

Neurogen Biomarking Announces Collaboration with Linus Health Bringing Easy Access to Cutting-Edge Technology to Support Early Detection of Mild Cognitive Impairment and Dementia due to Alzheimer's Disease.

Neurogen Biomarking, the world’s first ecosystem for memory loss with end-to-end patient support and Linus Health, a digital health company focused on transforming brain health for people worldwide, finalized an agreement to integrate Linus Health's scientifically-validated digital cognitive assessments into the Neurogen Biomarking ecosystem.